The clinical management of hepatocellular carcinoma in China: Progress and challenges.
作者信息
Shan Shan, Jia Jidong
机构信息
Liver Research Center, Beijing Friendship Hospital, Capital Medical University; The National Clinical Research Center for Digestive Diseases, Beijing, China.
出版信息
Clin Mol Hepatol. 2023 Apr;29(2):339-341. doi: 10.3350/cmh.2023.0077. Epub 2023 Mar 16.
Abstract
摘要
相似文献
1
The clinical management of hepatocellular carcinoma in China: Progress and challenges.中国肝细胞癌的临床管理：进展与挑战。
Clin Mol Hepatol. 2023 Apr;29(2):339-341. doi: 10.3350/cmh.2023.0077. Epub 2023 Mar 16.
2
Management of hepatocellular carcinoma in China: Seeking common grounds while reserving differences.中国肝细胞癌的管理：求同存异
Clin Mol Hepatol. 2023 Apr;29(2):342-344. doi: 10.3350/cmh.2023.0106. Epub 2023 Mar 16.
3
[Guidelines for diagnosis and treatment of primary liver cancer in China (2019 edition)].《中国原发性肝癌诊疗规范（2019年版）》
Zhonghua Gan Zang Bing Za Zhi. 2020 Feb 20;28(2):112-128. doi: 10.3760/cma.j.issn.1007-3418.2020.02.004.
4
[Clinical advances in targeted therapy and immunotherapy for hepatocellular carcinoma].[肝细胞癌靶向治疗与免疫治疗的临床进展]
Zhonghua Gan Zang Bing Za Zhi. 2019 Nov 20;27(11):834-837. doi: 10.3760/cma.j.issn.1007-3418.2019.11.005.
5
Hepatocellular carcinoma in the era of immunotherapy.免疫治疗时代的肝细胞癌
Curr Probl Cancer. 2018 Jan-Feb;42(1):40-48. doi: 10.1016/j.currproblcancer.2017.10.007. Epub 2017 Nov 15.
6
EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma.欧洲肝脏研究学会-欧洲肿瘤内科学会临床实践指南：肝细胞癌的管理
Eur J Cancer. 2012 Mar;48(5):599-641. doi: 10.1016/j.ejca.2011.12.021.
7
EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma.欧洲肝脏研究学会-欧洲肿瘤内科学会临床实践指南：肝细胞癌的管理
J Hepatol. 2012 Apr;56(4):908-43. doi: 10.1016/j.jhep.2011.12.001.
8
Hepatocellular carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up.肝细胞癌：ESMO关于诊断、治疗及随访的临床建议
Ann Oncol. 2008 May;19 Suppl 2:ii27-8. doi: 10.1093/annonc/mdn114.
9
Treatment strategy for hepatocellular carcinoma in China: radiofrequency ablation versus liver resection.中国肝细胞癌的治疗策略：射频消融与肝切除术对比
Jpn J Clin Oncol. 2016 Dec;46(12):1075-1080. doi: 10.1093/jjco/hyw134. Epub 2016 Sep 27.
10
Changes in and challenges regarding the surgical treatment of hepatocellular carcinoma in China.中国肝细胞癌外科治疗的变化与挑战。
Biosci Trends. 2021 Jul 6;15(3):142-147. doi: 10.5582/bst.2021.01083. Epub 2021 Mar 14.
引用本文的文献
1
Refining Prognosis and Treatment Strategies Beyond the Barcelona Clinic Liver Cancer Stage in Hepatocellular Carcinoma with Lung Metastases: A Multicenter Cohort Study.超越巴塞罗那临床肝癌分期优化肝细胞癌肺转移患者的预后及治疗策略：一项多中心队列研究
MedComm (2020). 2025 Aug 16;6(9):e70306. doi: 10.1002/mco2.70306. eCollection 2025 Sep.
2
SNRPB/CCNB1 axis promotes hepatocellular carcinoma progression and cisplatin resistance through enhancing lipid metabolism reprogramming.SNRPB/CCNB1轴通过增强脂质代谢重编程促进肝细胞癌进展和顺铂耐药。
J Exp Clin Cancer Res. 2025 Jul 18;44(1):211. doi: 10.1186/s13046-025-03463-y.
3
Tumor burden score and alpha-fetoprotein level predict prognosis of patients with unresectable hepatocellular carcinoma treated with tyrosine kinase inhibitor and anti-PD-1 antibody.肿瘤负荷评分和甲胎蛋白水平可预测接受酪氨酸激酶抑制剂和抗程序性死亡蛋白1抗体治疗的不可切除肝细胞癌患者的预后。
ILIVER. 2024 Aug 8;3(3):100109. doi: 10.1016/j.iliver.2024.100109. eCollection 2024 Sep.
4
Preparation and Evaluation of Hepatoma-Targeting Glycyrrhetinic Acid Composite Micelles Loaded with Curcumin.载姜黄素的肝癌靶向甘草次酸复合胶束的制备与评价
Pharmaceuticals (Basel). 2025 Mar 23;18(4):448. doi: 10.3390/ph18040448.
5
Camrelizumab plus rivoceranib compared sorafenib as first-line therapeutic options for advanced hepatocellular carcinoma in China: a cost-effectiveness analysis.在中国，卡瑞利珠单抗联合瑞戈非尼与索拉非尼作为晚期肝细胞癌一线治疗方案的成本效益分析。
BMJ Open. 2024 Dec 11;14(12):e079603. doi: 10.1136/bmjopen-2023-079603.
6
Biological impact and therapeutic implication of tumor-associated macrophages in hepatocellular carcinoma.肿瘤相关巨噬细胞在肝细胞癌中的生物学影响和治疗意义。
Cell Death Dis. 2024 Jul 12;15(7):498. doi: 10.1038/s41419-024-06888-z.
7
β-Sitosterol alleviates the malignant phenotype of hepatocellular carcinoma cells via inhibiting GSK3B expression.β-谷甾醇通过抑制 GSK3B 表达缓解肝癌细胞的恶性表型。
Hum Cell. 2024 Jul;37(4):1156-1169. doi: 10.1007/s13577-024-01081-y. Epub 2024 May 30.
8
How Possible Is the Elimination of Viral Hepatitis? An Analysis Based on the Global Burden of Disease from Hepatitis B and C, 1990-2019.消除病毒性肝炎的可能性有多大？基于1990 - 2019年全球乙肝和丙肝疾病负担的分析。
Microorganisms. 2024 Feb 15;12(2):388. doi: 10.3390/microorganisms12020388.
本文引用的文献
1
Global reporting of progress towards elimination of hepatitis B and hepatitis C.全球消除乙型肝炎和丙型肝炎进展报告。
Lancet Gastroenterol Hepatol. 2023 Apr;8(4):332-342. doi: 10.1016/S2468-1253(22)00386-7. Epub 2023 Feb 8.
2
Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Chinese perspective.肝细胞癌的临床实践指南和实际实践：中国视角。
Clin Mol Hepatol. 2023 Apr;29(2):206-216. doi: 10.3350/cmh.2022.0402. Epub 2022 Dec 22.
3
Management Algorithm for Prevention of Mother-to-child Transmission of Hepatitis B Virus (2022).《乙型肝炎病毒母婴传播预防管理算法（2022年版）》
J Clin Transl Hepatol. 2022 Oct 28;10(5):1004-1010. doi: 10.14218/JCTH.2022.00047. Epub 2022 Jun 21.
4
Impact of nationwide hepatocellular carcinoma surveillance on the prognosis in patients with chronic liver disease.全国性肝细胞癌监测对慢性肝病患者预后的影响。
Clin Mol Hepatol. 2022 Oct;28(4):851-863. doi: 10.3350/cmh.2022.0037. Epub 2022 Jun 3.
5
Ramucirumab as second-line treatment in Chinese patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein after sorafenib (REACH-2 China): A randomised, multicentre, double-blind study.雷莫西尤单抗作为索拉非尼治疗后甲胎蛋白升高的中国晚期肝细胞癌患者的二线治疗（REACH-2中国研究）：一项随机、多中心、双盲研究
EClinicalMedicine. 2022 Oct 6;54:101679. doi: 10.1016/j.eclinm.2022.101679. eCollection 2022 Dec.
6
[The consensus on tertiary prevention of primary liver cancer (2022 version)].《原发性肝癌三级预防共识（2022年版）》
Zhonghua Gan Zang Bing Za Zhi. 2022 Aug 20;30(8):832-845. doi: 10.3760/cma.j.cn501113-20220616-00330.
7
Epidemiological Characteristics of Primary Liver Cancer in Mainland China From 2003 to 2020: A Representative Multicenter Study.2003年至2020年中国大陆原发性肝癌的流行病学特征：一项代表性多中心研究
Front Oncol. 2022 Jun 21;12:906778. doi: 10.3389/fonc.2022.906778. eCollection 2022.
8
Consensus on the secondary prevention of primary liver cancer.原发性肝癌二级预防共识。
Hepatol Int. 2021 Dec;15(6):1289-1300. doi: 10.1007/s12072-021-10259-7. Epub 2021 Nov 30.
9
The best predictive model for hepatocellular carcinoma in patients with chronic hepatitis B infection.乙型肝炎感染患者肝细胞癌的最佳预测模型。
Clin Mol Hepatol. 2022 Jul;28(3):351-361. doi: 10.3350/cmh.2021.0281. Epub 2021 Nov 26.
10
Disparities in Hepatocellular Carcinoma Survival by Insurance Status: A Population-Based Study in China.保险状况对肝细胞癌生存的影响差异：中国的一项基于人群的研究。
Front Public Health. 2021 Nov 5;9:742355. doi: 10.3389/fpubh.2021.742355. eCollection 2021.
Zotero 插件